Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Acta Pharmaciae Indonesia : Acta Pharm Indo
Nadzif, Faradina Qorina
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Drug utilization of N-Acetylcysteine in COVID-19 inpatients at Santa Elisabeth Hospital, Purwokerto Ekowati, Heny; Nadzif, Faradina Qorina; Suryoputri, Masita Wulandari
Acta Pharmaciae Indonesia Vol 10 No 1 (2022): Acta Pharmaciae Indonesia : Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2022.10.1.5776

Abstract

Background: COVID-19 is associated to an oxidant-antioxidant imbalance, which leads to inflammation and tissue damage. N-Acetylcysteine (NAC), in addition to being a mucolytic, has been shown to be an effective antioxidant in the therapy of COVID-19. Objective: The purpose of this study is to evaluate at the NAC usage profile in COVID-19 inpatients at Santa Elisabeth Hospital in Purwokerto. Methods: A descriptive observational design was used to perform the study. Retrospective data were obtained from medical records from July 2020 to July 2021. All patients who met the inclusion criteria were sampled using the total sampling technique. Results: NAC was commonly administered to COVID-19 inpatients who have a mild illness of the disease. The most common symptoms were cough and fever. Patients with mild and moderate severity were given NAC orally (600 mg 3 times a day) and intravenously (5 gram/day), respectively. The duration of NAC administration was in the range of 8-14 days. Conclusion: NAC was one of the therapies used at Santa Elisabeth Hospital Purwokerto for COVID-19 inpatients.
The effectiveness of N-acetylcysteine in alleviating clinical Symptoms of COVID-19 hospitalized patients at Santa Elisabeth Purwokerto General Hospital, Indonesia Ekowati, Heny; Nadzif, Faradina Qorina; Suryoputri, Masita Wulandari; Endriastuti, Nialiana Endah; Baroroh, Hanif Nasiatul
Acta Pharmaciae Indonesia Vol 11 No 1 (2023): Acta Pharmaciae Indonesia : Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2023.11.1.7548

Abstract

Background: COVID-19 has been associated with increased innate immune system activation, leading to increased mucus production, inflammation, and tissue damage. N-Acetylcystysteine (NAC), an antioxidant and mucolytic, has demonstrated potential as a COVID-19 therapy. Objective: The purpose of this study was to evaluate the effectiveness of NAC on the clinical symptoms of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital in Indonesia. Methods: An observational analytical study design was employed, with data collected from the medical records of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital over the period of July 2020 to July 2021. The study included 209 patients who met the eligibility criteria. Results: The results indicated that the use of NAC affected the clinical symptoms of cough, oxygen saturation (SPO2), and respiratory rate in patients with mild and moderate degrees of COVID-19 patients (p<0.05). However, it was found not to affect patients with severe degrees of the disease (p>0.05). Conclusion: This study suggests that NAC may be a useful treatment option for patients with mild and moderate COVID-19. Further research is needed to confirm these findings and determine their effectiveness in severe cases.
Co-Authors Endriastuti, Nialiana Endah Hanif Nasiatul Baroroh Heny Ekowati Suryoputri, Masita Wulandari